NeuroMetrix has announced preliminary results from a clinical study of the Quell, a wearable pain relief device in subjects with chronic pain.
The study was a 60-day trial of Quell for treatment of chronic pain. The average age of the subjects was 56 years and 45% were female. Most had chronic pain for 1-10 years.
AdvertisementAccording to the company, the primary outcome measure was strongly positive with 81% of subjects rating Quell therapy as improving their chronic pain.
Also, secondary outcome measures were positive with 67% of subjects reporting a reduction in use of pain medications.
Shai N. Gozani, M.D., Ph.D. President and CEO of NeuroMetrix, Inc, said that the company is pleased with these results.
"They represent the first formal evaluation of self-administered wearable intensive nerve stimulation. Quell provided substantial pain relief and improvement in quality of life measures.
The primary outcome measure was impressive with 81% of subject's rating Quell therapy as improving their chronic pain and overall health. We were not surprised that two-thirds of the subjects reduced their use of pain medications, as we have consistently received this anecdotal feedback from Quell users over the past several months," Gozani said.
The study, "Treatment of Chronic Pain with a Novel Wearable Transcutaneous Electrical Nerve Stimulator", was accepted for poster presentation at the PAINWeek 2015 Scientific Sessions, September 8-12 in Las Vegas. An offcial representative of the company will present the study results.